MedTrace Logo

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

NCT05269121 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-02-22

No results posted yet for this study

Summary

This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without replacement of the prosthesis.

Conditions

Interventions

BIOLOGICAL

Phage Therapy

Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.

Sponsors & Collaborators

  • Adaptive Phage Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Hopkins, MD · Adaptive Phage Therapeutics, Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-11-30
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269121 on ClinicalTrials.gov